1 6693 128 VARIABLE INDUCTION OF PRDM1 AND DIFFERENTIATION IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH ANERGY. DESPITE ANTIGEN ENGAGEMENT AND INTACT B-CELL-RECEPTOR (BCR) SIGNALING, CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS FAIL TO UNDERGO TERMINAL DIFFERENTIATION. WE HYPOTHESIZED THAT SUCH FAILURE MAY BE DUE TO ANERGY, AS CLL CELLS EXHIBIT VARIABLE LEVELS OF NONRESPONSIVENESS TO SURFACE IGM STIMULATION THAT IS REVERSIBLE IN VITRO. MOREOVER, ANERGY IS ASSOCIATED WITH REDUCED DIFFERENTIATION CAPACITY IN NORMAL B CELLS. WE INVESTIGATED RESPONSES OF CLL CELLS TO TWO POTENT DIFFERENTIATION-PROMOTING AGENTS, IL-21 AND CYTOSINE GUANINE DINUCLEOTIDE-ENRICHED OLIGO-DEOXYNUCLEOTIDES. THE INDUCTION OF PR DOMAIN-CONTAINING PROTEIN 1 (PRDM1; ALSO KNOWN AS BLIMP-1), A CRITICAL REGULATOR OF PLASMACYTIC DIFFERENTIATION, BY THESE AGENTS WAS CLOSELY CORRELATED BUT VARIED BETWEEN INDIVIDUAL CASES, DESPITE FUNCTIONALLY INTACT IL-21 RECEPTOR- AND TOLL-LIKE RECEPTOR 9-MEDIATED SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3, AND NUCLEAR FACTOR-KAPPAB PATHWAYS. PRDM1 INDUCTION WAS INVERSELY CORRELATED WITH THE EXTENT OF ANERGY AS MEASURED BY THE ABILITY TO MOBILIZE INTRACELLULAR CA(2+) FOLLOWING BCR CROSSLINKING. PRDM1 RESPONSIVENESS WAS ASSOCIATED WITH OTHER MARKERS OF DIFFERENTIATION AND PROLIFERATION BUT NOT WITH DIFFERENCES IN APOPTOSIS. THE ABILITY TO INDUCE PRDM1 DID CORRELATE WITH DIFFERENTIAL TRANSCRIPTIONAL AND EPIGENETIC REGULATION OF THE PRDM1 GENE. THESE STUDIES EXTEND OUR UNDERSTANDING OF CLL PATHOBIOLOGY, DEMONSTRATING THAT REDUCED DIFFERENTIATION CAPACITY MAY BE A CONSEQUENCE OF ANERGY. EPIGENETIC DRUGS MAY OFFER POSSIBILITIES TO REACTIVATE PRDM1 EXPRESSION AS PART OF NOVEL DIFFERENTIATION THERAPY APPROACHES. 2014 2 2787 32 EZH2-MEDIATED EPIGENETIC MODIFICATION IS REQUIRED FOR ALLOGENEIC T CELL-INDUCED LUPUS DISEASE. BACKGROUND: THE MECHANISMS INVOLVED IN THE PATHOGENESIS OF AUTOIMMUNE DISORDERS, INCLUDING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), HAVE NOT BEEN FULLY ELUCIDATED. SOME OF THESE MECHANISMS INVOLVE EPIGENETIC REGULATION OF GENE EXPRESSION. THE HISTONE METHYLTRANSFERASE EZH2 CONTRIBUTES TO EPIGENETIC REGULATION OF GENE EXPRESSION, IS HIGHLY EXPRESSED IN GERMINAL CENTER (GC) B CELLS AND FOLLICULAR T HELPER (T(FH)) CELLS, AND MAY BE INVOLVED IN LUPUS PATHOGENESIS. METHODS: THE MURINE BM12 MODEL OF LUPUS-LIKE CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) WAS INDUCED BY INTRA-PERITONEAL INJECTION OF NEGATIVELY ISOLATED ALLOGENEIC CD4(+) T CELLS. LUPUS-LIKE DISEASE DEVELOPMENT WAS MONITORED BY ELISA DETERMINATION OF SERUM ANTI-DSDNA AND ANTI-CHROMATIN ANTIBODY TITERS. IMMUNE CELL ACTIVATION AND EZH2 EXPRESSION WERE EVALUATED BY FLOW CYTOMETRY AND WESTERN BLOTTING. RESULTS: DECREASED AUTOANTIBODY PRODUCTION AND GC FORMATION ARE OBSERVED WHEN EZH2-DEFICIENT CD4(+) T CELLS ARE USED INSTEAD OF WILD-TYPE (WT) TO INDUCE CGVHD AND WHEN MICE THAT RECEIVE ALLOGENEIC WT DONOR T CELLS TO INDUCE CGVHD ARE TREATED WITH GSK503, AN EZH2-SPECIFIC INHIBITOR. IN THE BM12 CGVHD MODEL, WT DONOR T CELLS ARE NORMALLY FULLY ACTIVATED 1 WEEK AFTER INFUSION INTO AN ALLOGENEIC HOST, EXHIBIT A T(FH) CELL (PD-1(HI)/CXCR5(HI)) PHENOTYPE WITH UPREGULATED EZH2, AND ACTIVATE B CELLS TO FORM GERMINAL CENTERS (GCS). IN CONTRAST, EZH2-DEFICIENT DONOR T CELLS GENERATE FEWER T(FH) CELLS THAT FAIL TO ACTIVATE B CELLS OR PROMOTE GC FORMATION. DESPITE SIMILAR T-INDEPENDENT, LPS-INDUCED B CELL RESPONSES, OVA-IMMUNIZED CD4.EZH2-KO MICE HAD A SKEWED LOW-AFFINITY IGM PHENOTYPE IN COMPARISON TO SIMILARLY TREATED WT MICE. IN ADDITION, EARLY AFTER OVA IMMUNIZATION, MORE CD4(+) T CELLS FROM B6.CD4.EZH2-KO MICE HAD A CD44(LO)/CD62L(LO) PHENOTYPE, WHICH SUGGESTS ARRESTED OR DELAYED ACTIVATION, THAN CD4(+) T CELLS FROM OVALBUMIN-IMMUNIZED B6.WT MICE. CONCLUSION: EZH2 GENE DELETION OR PHARMACOLOGICAL EZH2 INHIBITION SUPPRESSES AUTOANTIBODY PRODUCTION AND GC FORMATION IN BM12 LUPUS-LIKE CGVHD AND DECREASES AFFINITY MATURATION AND ISOTYPE SWITCHING IN RESPONSE TO IMMUNIZATION WITH A T CELL-DEPENDENT ANTIGEN. EZH2 INHIBITION MAY BE USEFUL FOR THE TREATMENT OF LUPUS AND OTHER AUTOIMMUNE DISORDERS. 2020 3 1001 36 CHRONIC TCDD EXPOSURE RESULTS IN THE DYSREGULATION OF GENE EXPRESSION IN SPLENIC B-LYMPHOCYTES AND IN THE IMPAIRMENTS IN T-CELL AND B-CELL DIFFERENTIATION IN MOUSE MODEL. 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN (TCDD) EXPOSURE IN HUMANS IS ASSOCIATED WITH MARKED IMMUNE SUPPRESSIONS AND INCREASED INCIDENCE OF LYMPHOBLASTIC DISEASES. TO ELUCIDATE MECHANISMS OF IMPAIRMENTS IN HUMORAL IMMUNE RESPONSES, WE USED A MURINE MODEL. FOLLOWING A 20-WEEK ADMINISTRATION OF LOW DOSES OF TCDD, WE OBSERVED SEVERELY REDUCED ANTIBODY TITERS, DRAMATICALLY DECREASED NUMBER OF SPLENIC TH1 AND TH2 CELLS AND AN INCREASE IN CD19(+) B CELLS. TRANSCRIPTIONAL PROFILING OF CD19(+) B CELLS SHOWED THAT MARKERS OF PRE-B CELLS WERE SIGNIFICANTLY ELEVATED, INDICATING DELAYED B CELL MATURATION. THESE CHANGES IN B CELLS WERE ACCOMPANIED BY DECREASES OF T HELPER CELL NUMBERS AND REDUCED IGM AND IGG TITERS. A TRANSCRIPTOME ANALYSIS OF SPLENIC B CELLS FOLLOWED BY INGENUITY PATHWAY ANALYSIS (IPA) REVEALED A SET OF DIFFERENTIALLY EXPRESSED GENES KNOWN TO PLAY ROLES IN TUMORIGENESIS, CELL-PROLIFERATION AND CELL-MIGRATION. THE MOST UP-REGULATED TRANSCRIPT GENE WAS EPH RECEPTOR A2 (EPHA2), A KNOWN ONCOGENE, AND THE MOST DOWN-REGULATED TRANSCRIPT WAS ZBTB16 THAT CODES FOR A NEGATIVE TRANSCRIPTIONAL REGULATOR IMPORTANT IN EPIGENETIC CHROMATIN REMODELING. IPA IDENTIFIED CAMP-RESPONSIVE ELEMENT MODULATOR (CREM) AND CAMP-RESPONSIVE ELEMENT BINDING PROTEIN 1 (CREB1) AS TOP UPSTREAM REGULATORS. CONSISTENTLY, A MAPPER PROMOTER DATABASE ANALYSIS SHOWED THAT ALL TOP DYSREGULATED GENES HAD CREM AND/OR CREB1 BINDING SITES IN THEIR PROMOTER REGIONS. IN SUMMARY, OUR DATA SHOWED THAT CHRONIC TCDD EXPOSURE IN MICE CAUSED SUPPRESSED HUMORAL IMMUNITY ACCOMPANIED WITH PROFOUND DYSREGULATION OF GENE EXPRESSION IN SPLENIC B-LYMPHOCYTES, LIKELY THROUGH CAMP-DEPENDENT PATHWAYS. THIS DYSREGULATION RESULTED IN IMPAIRMENTS IN T-CELL AND B-CELL DIFFERENTIATION AND ACTIVATION OF THE TUMORIGENIC TRANSCRIPTION PROGRAM. 2016 4 4123 34 MECHANISMS OF DIMETHYLBENZANTHRACENE-INDUCED IMMUNOTOXICITY. TRADITIONAL METHODS FOR TOXICOLOGICAL ASSESSMENT HAVE IMPLICATED THE IMMUNE SYSTEM AS A FREQUENT TARGET ORGAN OF TOXIC INSULT FOLLOWING CHRONIC EXPOSURE TO CERTAIN ENVIRONMENTAL CHEMICALS, RADIATION OR THERAPEUTIC DRUGS (XENOBIOTICS). IMMUNOTOXICITY IS EXPRESSED AS AUTOIMMUNITY, CHEMICAL HYPERSENSITIVITY OR IMMUNOSUPPRESSION. A TIERED APPROACH FOR CHARACTERIZING CHEMICAL AND DRUG-INDUCED IMMUNOMODULATION HAS BEEN DEVELOPED AND VALIDATED IN LABORATORY ANIMALS. POLYCYCLIC AROMATIC HYDROCARBONS (PAH) HAVE BEEN STUDIED BECAUSE OF THEIR UBIQUITOUS PRESENCE IN THE ENVIRONMENT AND CARCINOGENIC POTENTIAL. SINCE IMMUNOSUPPRESSION INDUCED BY PAH CARCINOGENS HAS BEEN IMPLICATED AS AN EPIGENETIC MECHANISM IN THE OUTGROWTH OF INITIATED CELLS, THIS TIERED APPROACH WAS USED TO CHARACTERIZE THE MECHANISM OF PAH IMMUNOSUPPRESSIVE CAPACITY. PREVIOUSLY, STUDIES IN THIS LABORATORY HAVE DEMONSTRATED THAT SUBCHRONIC EXPOSURE OF B6C3F1 MICE TO PAH CARCINOGENS SUPPRESSES BOTH HUMORAL IMMUNITY (HI) AND CELL-MEDIATED IMMUNITY (CMI), CONCURRENTLY WITH DECREASED RESISTANCE TO TUMOR CHALLENGE. THE POTENT CARCINOGENIC PAH, 7,12-DIMETHYLBENZ[A]ANTHRACENE (DMBA) WAS SUBCHRONICALLY ADMINISTERED SUBCUTANEOUSLY AT 5, 50, OR 100 MICROGRAMS/G OF BODY WEIGHT. NATURAL KILLER (NK) CELL TUMOR CYTOLYSIS, GENERATION OF CYTOTOXIC T-CELLS (CTL), AND LYMPHOPROLIFERATION TO MITOGENS AND ALLOGENEIC SPLENOCYTES IN MIXED LEUKOCYTE CULTURES (MLC) WERE QUANTITATED 3-5 DAYS AFTER EXPOSURE TO ASSESS CMI. MITOGEN AND ALLOANTIGEN-INDUCED PROLIFERATION (MLC) OF SPLENOCYTES WAS SUPPRESSED UP TO 90%. CTL AND NK TUMOR CYTOLYSIS OF RADIOLABELLED TARGET CELLS WERE SIMILARLY DEPRESSED UP TO 88 AND 82%, RESPECTIVELY. IMPAIRMENT OF MLC OR CTL RESPONSES CORRELATED WITH INCREASED SUSCEPTIBILITY TO CHALLENGE WITH PYB6 SARCOMA CELLS. HI WAS MEASURED BY QUANTITATING THE NUMBER OF ANTIBODY (IGM) PLAQUE-FORMING CELLS (PFC) PRODUCED IN RESPONSE TO T-CELL DEPENDENT ANTIGEN CHALLENGE (SHEEP ERYTHROCYTES) AND WAS SIMILARLY SUPPRESSED UP TO 95%. TO UNDERSTAND THE MECHANISM OF PAH-INDUCED IMMUNOTOXICITY, SPLENOCYTES FROM DMBA-EXPOSED MICE WERE SENSITIZED TO ALLOANTIGENS IN THE PRESENCE OF INTERLEUKIN-2 (IL-2) BECAUSE THERE WERE INDICATIONS THAT T-HELPER CELL FUNCTION WAS SUPPRESSED. IN THESE PRELIMINARY STUDIES, CTL SUPPRESSION COULD BE COMPLETELY RESTORED BY THE ADDITION OF THE T-CELL GROWTH SUPPORTING LYMPHOKINE (IL-2) DURING THE INDUCTIVE PHASE OF CTL GENERATION, SUGGESTING THAT DMBA EXPOSURE DIRECTLY OR INDIRECTLY INDUCED DEFICITS IN T-HELPER CELL FUNCTION. 1985 5 3522 39 IL-10 PRODUCTION BY CLL CELLS IS ENHANCED IN THE ANERGIC IGHV MUTATED SUBSET AND ASSOCIATES WITH REDUCED DNA METHYLATION OF THE IL10 LOCUS. CHRONIC LYMPHOCYTIC LEUKEMIAS (CLLS) WITH UNMUTATED (U-CLL) OR MUTATED (M-CLL) IGHV HAVE VARIABLE FEATURES OF IMMUNOSUPPRESSION, POSSIBLY INFLUENCED BY THOSE CLL CELLS ACTIVATED TO PRODUCE INTERLEUKIN 10 (IL-10). THE TWO SUBSETS DIFFER IN THEIR LEVELS OF ANERGY, DEFINED BY LOW SURFACE IMMUNOGLOBULIN M LEVELS/SIGNALING CAPACITY, AND IN THEIR DNA METHYLATION PROFILE, PARTICULARLY VARIABLE IN M-CLL. WE HAVE NOW FOUND THAT LEVELS OF IL-10 PRODUCED BY ACTIVATED CLL CELLS WERE HIGHLY VARIABLE. LEVELS WERE HIGHER IN M-CLL THAN IN U-CLL AND CORRELATED WITH ANERGY. DNA METHYLATION ANALYSIS OF IL10 LOCUS REVEALED TWO PREVIOUSLY UNCHARACTERIZED 'VARIABLY METHYLATED REGIONS' (CLL-VMRS1/2) IN THE GENE BODY, BUT SIMILARLY LOW METHYLATION IN THE PROMOTER OF BOTH U-CLL AND M-CLL. CLL-VMR1/2 METHYLATION WAS LOWER IN M-CLL THAN IN U-CLL AND INVERSELY CORRELATED WITH IL-10 INDUCTION. A FUNCTIONAL SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) BINDING SITE IN CLL-VMR2 WAS CONFIRMED BY PROXIMITY LIGATION AND LUCIFERASE ASSAYS, WHEREAS INHIBITION OF SYK-MEDIATED STAT3 ACTIVATION RESULTED IN SUPPRESSION OF IL10. THE DATA SUGGEST EPIGENETIC CONTROL OF IL-10 PRODUCTION. HIGHER TUMOR LOAD MAY COMPENSATE THE REDUCED IL-10 PRODUCTION IN U-CLL, ACCOUNTING FOR CLINICAL IMMUNOSUPPRESSION IN BOTH SUBSETS. THE OBSERVATION THAT SYK INHIBITION ALSO SUPPRESSES IL-10 PROVIDES A POTENTIAL NEW RATIONALE FOR THERAPEUTIC TARGETING AND IMMUNOLOGICAL RESCUE BY SYK INHIBITORS IN CLL. 2017 6 6611 27 UHRF1 REGULATES GERMINAL CENTER B CELL EXPANSION AND AFFINITY MATURATION TO CONTROL VIRAL INFECTION. THE PRODUCTION OF HIGH-AFFINITY ANTIBODY IS ESSENTIAL FOR PATHOGEN CLEARANCE. ANTIBODY AFFINITY IS INCREASED THROUGH GERMINAL CENTER (GC) AFFINITY MATURATION, WHICH RELIES ON BCR SOMATIC HYPERMUTATION (SHM) FOLLOWED BY ANTIGEN-BASED SELECTION. GC B CELL PROLIFERATION IS ESSENTIALLY INVOLVED IN THESE PROCESSES; IT PROVIDES ENOUGH TEMPLATES FOR SHM AND ALSO SERVES AS A CRITICAL MECHANISM OF POSITIVE SELECTION. IN THIS STUDY, WE SHOW THAT EXPRESSION OF EPIGENETIC REGULATOR UBIQUITIN-LIKE WITH PHD AND RING FINGER DOMAINS 1 (UHRF1) WAS MARKEDLY UP-REGULATED BY C-MYC-AP4 IN GC B CELLS, AND IT WAS REQUIRED FOR GC RESPONSE. UHRF1 REGULATES CELL PROLIFERATION-ASSOCIATED GENES INCLUDING CDKN1A, SLFN1, AND SLFN2 BY DNA METHYLATION, AND ITS DEFICIENCY INHIBITED THE GC B CELL CYCLE AT G1-S PHASE. SUBSEQUENTLY, GC B CELL SHM AND AFFINITY MATURATION WERE IMPAIRED, AND UHRF1 GC B KNOCKOUT MICE WERE UNABLE TO CONTROL CHRONIC VIRUS INFECTION. COLLECTIVELY, OUR DATA SUGGEST THAT UHRF1 REGULATES GC B CELL PROLIFERATION AND AFFINITY MATURATION, AND ITS EXPRESSION IN GC B CELLS IS REQUIRED FOR VIRUS CLEARANCE. 2018 7 912 14 CHRONIC EXPOSURE TO WATER POLLUTANT TRICHLOROETHYLENE INCREASED EPIGENETIC DRIFT IN CD4(+) T CELLS. AIM: AUTOIMMUNE DISEASE AND CD4(+) T-CELL ALTERATIONS ARE INDUCED IN MICE EXPOSED TO THE WATER POLLUTANT TRICHLOROETHYLENE (TCE). WE EXAMINED HERE WHETHER TCE ALTERED GENE-SPECIFIC DNA METHYLATION IN CD4(+) T CELLS AS A POSSIBLE MECHANISM OF IMMUNOTOXICITY. MATERIALS & METHODS: NAIVE AND EFFECTOR/MEMORY CD4(+) T CELLS FROM MICE EXPOSED TO TCE (0.5 MG/ML IN DRINKING WATER) FOR 40 WEEKS WERE EXAMINED BY BISULFITE NEXT-GENERATION DNA SEQUENCING. RESULTS: A PROBABILISTIC MODEL CALCULATED FROM MULTIPLE GENES SHOWED THAT TCE DECREASED METHYLATION CONTROL IN CD4(+) T CELLS. DATA FROM INDIVIDUAL GENES FITTED TO A QUADRATIC REGRESSION MODEL SHOWED THAT TCE INCREASED GENE-SPECIFIC METHYLATION VARIANCE IN BOTH CD4 SUBSETS. CONCLUSION: TCE INCREASED EPIGENETIC DRIFT OF SPECIFIC CPG SITES IN CD4(+) T CELLS. 2016 8 2765 31 EXPRESSION, EPIGENETIC REGULATION, AND HUMORAL IMMUNOGENICITY OF CANCER-TESTIS ANTIGENS IN CHRONIC MYELOID LEUKEMIA. OBJECTIVE: CANCER-TESTIS (CT) ANTIGENS REPRESENT ATTRACTIVE TARGETS FOR TUMOR IMMUNOTHERAPY BASED ON THEIR TUMOR-RESTRICTED EXPRESSION AND IMMUNOGENICITY. HOWEVER, A BROAD PICTURE OF THE EXPRESSION OF CT ANTIGENS AND ASSOCIATED HUMORAL IMMUNE RESPONSES IN CHRONIC MYELOID LEUKEMIA (CML) IS STILL MISSING. METHODS: WE SCREENED CML CELL LINES AND BONE MARROW (BM) SAMPLES FROM HEALTHY DONORS BY RT-PCR FOR THE EXPRESSION OF 31 CT ANTIGENS BEFORE AND AFTER TREATMENT WITH EPIGENETIC AGENTS. EXPRESSION OF TUMOR-RESTRICTED ANTIGENS WAS FURTHER EXAMINED IN 60 CML PATIENTS AND HUMORAL IMMUNE RESPONSES AGAINST 15 CT ANTIGENS WERE SCREENED BY ELISA. RESULTS: IN UNTREATED CELL LINES WE DETECTED THE EXPRESSION OF 17 CT ANTIGENS THAT WERE ABSENT FROM NORMAL BM. EXPRESSION OF MOST ANTIGENS INCREASED FOLLOWING DEMETHYLATING TREATMENT WITH 5'-AZA-2'-DEOXYCYTIDINE. IN THESE SAMPLES, ONLY PRAME WAS REPEATEDLY DETECTED AND EXPRESSION CORRELATED WITH SEVERAL CLINICOPATHOLOGICAL PARAMETERS AND DECREASED OVERALL SURVIVAL. WE FURTHER SHOW THAT A LOWER FREQUENCY OF PRAME-POSITIVE SAMPLES DURING IMATINIB TREATMENT WAS NOT CAUSED BY GENE-SPECIFIC DOWNREGULATION. ANALYZING THE PATIENTS' ANTIBODY RESPONSES WE FOUND THAT THE VAST MAJORITY OF PATIENTS LACKED SPONTANEOUS IMMUNITY AGAINST CT ANTIGENS INCLUDING PRAME. CONCLUSIONS: CT ANTIGEN EXPRESSION CAN BE INCREASED BY THE APPLICATION OF EPIGENETIC AGENTS AND THE EXPRESSION OF PRAME CORRELATES WITH CLINICOPATHOLOGICAL PARAMETERS AND OVERALL SURVIVAL IN PATIENTS WITH CML, BUT DOES NOT LEAD TO HUMORAL IMMUNE RESPONSES. PRAME-SPECIFIC IMMUNOTHERAPY MIGHT REPRESENT A PROMISING APPROACH FOR THE ERADICATION OF RESIDUAL THERAPY-RESISTANT LEUKEMIC CELLS DUE TO ITS FREQUENT EXPRESSION AND STABILITY UNDER IMATINIB TREATMENT. 2010 9 991 29 CHRONIC STIMULATION DRIVES HUMAN NK CELL DYSFUNCTION AND EPIGENETIC REPROGRAMING. A POPULATION OF NATURAL KILLER (NK) CELLS EXPRESSING THE ACTIVATING RECEPTOR NKG2C AND THE MATURATION MARKER CD57 EXPANDS IN RESPONSE TO HUMAN CYTOMEGALOVIRUS (HCMV) INFECTION. CD3-CD56DIMCD57+NKG2C+ NK CELLS ARE SIMILAR TO CD8+ MEMORY T CELLS WITH RAPID AND ROBUST EFFECTOR FUNCTION UPON RE-STIMULATION, PERSISTENCE, AND EPIGENETIC REMODELING OF THE IFNG LOCUS. CHRONIC ANTIGEN STIMULATION DRIVES CD8+ MEMORY T CELL PROLIFERATION WHILE ALSO INDUCING GENOME-WIDE EPIGENETIC REPROGRAMING AND DYSFUNCTION. WE HYPOTHESIZED THAT CHRONIC STIMULATION COULD SIMILARLY INDUCE EPIGENETIC REPROGRAMING AND DYSFUNCTION IN NK CELLS. HERE WE SHOW THAT CHRONIC STIMULATION OF ADAPTIVE NK CELLS THROUGH NKG2C USING PLATE-BOUND AGONISTIC ANTIBODIES IN COMBINATION WITH IL-15 DROVE ROBUST PROLIFERATION AND ACTIVATION OF CD3-CD56DIMCD57+NKG2C+ NK CELLS WHILE SIMULTANEOUSLY INDUCING HIGH EXPRESSION OF THE CHECKPOINT INHIBITORY RECEPTORS LAG-3 AND PD-1. MARKED INDUCTION OF CHECKPOINT INHIBITORY RECEPTORS WAS ALSO OBSERVED ON THE SURFACE OF ADAPTIVE NK CELLS CO-CULTURED WITH HCMV-INFECTED ENDOTHELIAL CELLS. CHRONICALLY STIMULATED ADAPTIVE NK CELLS WERE DYSFUNCTIONAL WHEN CHALLENGED WITH TUMOR TARGETS. THESE CELLS EXHIBITED A PATTERN OF EPIGENETIC REPROGRAMING, WITH GENOME-WIDE ALTERATIONS IN DNA METHYLATION. OUR STUDY HAS IMPORTANT IMPLICATIONS FOR CANCER IMMUNOTHERAPY AND SUGGEST THAT EXHAUSTED NK CELLS COULD BE TARGETED WITH INHIBITORY CHECKPOINT RECEPTOR BLOCKADE. 2019 10 1986 29 EPIGENETIC ALTERATIONS MAY REGULATE TEMPORARY REVERSAL OF CD4(+) T CELL ACTIVATION CAUSED BY TRICHLOROETHYLENE EXPOSURE. PREVIOUS STUDIES HAVE SHOWN THAT SHORT-TERM (4 WEEKS) OR CHRONIC (32 WEEKS) EXPOSURE TO TRICHLOROETHYLENE (TCE) IN DRINKING WATER OF FEMALE MRL+/+ MICE GENERATED CD4(+) T CELLS THAT SECRETED INCREASED LEVELS OF INTERFERON (IFN)-GAMMA AND EXPRESSED AN ACTIVATED (CD44(HI)CD62L(LO)) PHENOTYPE. IN CONTRAST, THE CURRENT STUDY OF SUBCHRONIC TCE EXPOSURE SHOWED THAT MIDWAY IN THE DISEASE PROCESS BOTH OF THESE PARAMETERS OF CD4(+) T CELL ACTIVATION WERE REVERSED. THIS PHASE OF THE DISEASE PROCESS MAY REPRESENT AN ATTEMPT BY THE BODY TO COUNTERACT THE INFLAMMATORY EFFECTS OF TCE. THE DECREASE IN CD4(+) T CELL PRODUCTION OF IFN-GAMMA FOLLOWING SUBCHRONIC TCE EXPOSURE COULD NOT BE ATTRIBUTED TO SKEWING TOWARD A TH2 OR TH17 PHENOTYPE OR TO AN INCREASE IN TREG CELLS. INSTEAD, THE SUPPRESSION CORRESPONDED TO ALTERATIONS IN MARKERS USED TO ASSESS DNA METHYLATION, NAMELY INCREASED EXPRESSION OF RETROTRANSPOSONS IAP (INTRACISTERNAL A PARTICLE) AND MUERV (MURINE ENDOGENOUS RETROVIRUS). ALSO OBSERVED WAS AN INCREASE IN THE EXPRESSION OF DNMT1 (DNA METHYLTRANSFERASE-1) AND DECREASED EXPRESSION OF SEVERAL GENES KNOWN TO BE DOWNREGULATED BY DNA METHYLATION, NAMELY IFNG, IL2, AND CDKN1A. CD4(+) T CELLS FROM A SECOND STUDY IN WHICH MRL+/+ MICE WERE TREATED FOR 17 WEEKS WITH TCE SHOWED A SIMILAR INCREASE IN IAP AND DECREASE IN CDKN1A. IN ADDITION, DNA COLLECTED FROM THE CD4(+) T CELLS IN THE SECOND STUDY SHOWED TCE-DECREASED GLOBAL DNA METHYLATION. THUS, THESE RESULTS DESCRIBED THE BIPHASIC NATURE OF TCE-INDUCED ALTERATIONS IN CD4(+) T CELL FUNCTION AND SUGGESTED THAT THESE CHANGES REPRESENTED POTENTIALLY REVERSIBLE ALTERATIONS IN EPIGENETIC PROCESSES. 2012 11 3953 28 LOCUS-SPECIFIC REVERSIBLE DNA METHYLATION REGULATES TRANSIENT IL-10 EXPRESSION IN TH1 CELLS. IL-10 IS A PLEIOTROPIC CYTOKINE WITH MULTIFACETED FUNCTIONS IN ESTABLISHING IMMUNE HOMEOSTASIS. ALTHOUGH EXPRESSED BY TH1 AND TH2 CELLS, CONVENTIONAL TH1 CELLS PRODUCE MARGINAL LEVELS OF IL-10 COMPARED WITH THEIR TH2 COUNTERPARTS. IN THIS STUDY, WE INVESTIGATED THE EPIGENETIC MECHANISMS OF IL-10 GENE EXPRESSION IN TH1 CELLS. BIOINFORMATICS EMBOSS CPG PLOT ANALYSIS AND BISULFITE PYROSEQUENCING REVEALED THREE CPG DNA METHYLATION SITES IN THE IL-10 GENE LOCUS. PROGRESSIVE DNA METHYLATION AT ALL OF THE CPG REGIONS OF INTEREST (ROIS) ESTABLISHED A REPRESSIVE PROGRAM OF IL-10 GENE EXPRESSION IN TH1 CELLS. INTERESTINGLY, TH1 CELLS TREATED WITH IL-12 AND IL-27 CYTOKINES, THEREBY MIMICKING A CHRONIC INFLAMMATORY CONDITION IN VIVO, DISPLAYED A SIGNIFICANT INCREASE IN IL-10 PRODUCTION THAT WAS ACCOMPANIED BY SELECTIVE DNA DEMETHYLATION AT ROI 3 LOCATED IN INTRON 3. IL-10-PRODUCING T CELLS ISOLATED FROM LYMPHOCYTIC CHORIOMENINGITIS VIRUS-INFECTED MICE ALSO SHOWED ENHANCED DNA DEMETHYLATION AT ROI 3. BINDING OF STAT1 AND STAT3 TO DEMETHYLATED ROI 3 ENHANCED IL-10 EXPRESSION IN AN IL-12/IL-27-DEPENDENT MANNER. ACCORDINGLY, CD4(+) T CELLS ISOLATED FROM STAT1- OR STAT3-KNOCKOUT MICE WERE SIGNIFICANTLY DEFECTIVE IN IL-10 PRODUCTION. OUR DATA SUGGEST THAT, ALTHOUGH STABLY MAINTAINED DNA METHYLATION AT THE PROMOTER MAY REPRESS IL-10 EXPRESSION IN TH1 CELLS, LOCUS-SPECIFIC REVERSIBLE DNA DEMETHYLATION MAY SERVE AS A THRESHOLD PLATFORM TO CONTROL TRANSIENT IL-10 GENE EXPRESSION. 2018 12 5223 40 PRIMARY MURINE CD4+ T CELLS FAIL TO ACQUIRE THE ABILITY TO PRODUCE EFFECTOR CYTOKINES WHEN ACTIVE RAS IS PRESENT DURING TH1/TH2 DIFFERENTIATION. CONSTITUTIVE RAS SIGNALING HAS BEEN SHOWN TO AUGMENT IL-2 PRODUCTION, REVERSE ANERGY, AND FUNCTIONALLY REPLACE MANY ASPECTS OF CD28 CO-STIMULATION IN CD4+ T CELLS. THESE DATA RAISE THE POSSIBILITY THAT INTRODUCTION OF ACTIVE RAS INTO PRIMARY T CELLS MIGHT RESULT IN IMPROVED FUNCTIONALITY IN PATHOLOGIC SITUATIONS OF T CELL DYSFUNCTION, SUCH AS CANCER OR CHRONIC VIRAL INFECTION. TO TEST THE BIOLOGIC EFFECTS OF ACTIVE RAS IN PRIMARY T CELLS, CD4+ T CELLS FROM COXSACKIE-ADENOVIRUS RECEPTOR TRANSGENIC MICE WERE TRANSDUCED WITH AN ADENOVIRUS ENCODING ACTIVE RAS. AS EXPECTED, ACTIVE RAS AUGMENTED IL-2 PRODUCTION IN NAIVE CD4+ T CELLS. HOWEVER, WHEN CELLS WERE CULTURED FOR 4 DAYS UNDER CONDITIONS TO PROMOTE EFFECTOR CELL DIFFERENTIATION, ACTIVE RAS INHIBITED THE ABILITY OF CD4+ T CELLS TO ACQUIRE A TH1 OR TH2 EFFECTOR CYTOKINE PROFILE. THIS DIFFERENTIATION DEFECT WAS NOT DUE TO DEFICIENT STAT4 OR STAT6 ACTIVATION BY IL-12 OR IL-4, RESPECTIVELY, NOR WAS IT ASSOCIATED WITH DEFICIENT INDUCTION OF T-BET AND GATA-3 EXPRESSION. IMPAIRED EFFECTOR CYTOKINE PRODUCTION IN ACTIVE RAS-TRANSDUCED CELLS WAS ASSOCIATED WITH DEFICIENT DEMETHYLATION OF THE IL-4 GENE LOCUS. OUR RESULTS INDICATE THAT, DESPITE AUGMENTING ACUTE ACTIVATION OF NAIVE T CELLS, CONSTITUTIVE RAS SIGNALING INHIBITS THE ABILITY OF CD4+ T CELLS TO PROPERLY DIFFERENTIATE INTO TH1/TH2 EFFECTOR CYTOKINE-PRODUCING CELLS, IN PART BY INTERFERING WITH EPIGENETIC MODIFICATION OF EFFECTOR GENE LOCI. ALTERNATIVE STRATEGIES TO POTENTIATE RAS PATHWAY SIGNALING IN T CELLS IN A MORE REGULATED FASHION SHOULD BE CONSIDERED AS A THERAPEUTIC APPROACH TO IMPROVE IMMUNE RESPONSES IN VIVO. 2014 13 5319 30 PTEN IS FUNDAMENTAL FOR ELIMINATION OF LEUKEMIA STEM CELLS MEDIATED BY GSK126 TARGETING EZH2 IN CHRONIC MYELOGENOUS LEUKEMIA. PURPOSE: LEUKEMIA STEM CELLS (LSCS) ARE AN IMPORTANT SOURCE OF TYROSINE KINASE INHIBITOR RESISTANCE AND DISEASE RELAPSE IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML). TARGETING LSCS MAY BE AN ATTRACTIVE STRATEGY TO OVERRIDE THIS THORNY PROBLEM. GIVEN THAT EZH2 WAS OVEREXPRESSED IN PRIMARY CML CD34(+) CELLS, OUR PURPOSE IN THIS STUDY WAS TO EVALUATE THE EFFECTS OF TARGETING EZH2 ON CML LSCS AND CLARIFY ITS UNDERLYING MECHANISM.EXPERIMENTAL DESIGN: HUMAN PRIMARY CML CD34(+) CELLS AND RETROVIRALLY BCR-ABL-DRIVEN CML MOUSE MODELS WERE EMPLOYED TO EVALUATE THE EFFECTS OF SUPPRESSION OF EZH2 BY GSK126- OR EZH2-SPECIFIC SHRNA IN VITRO AND IN VIVO RECRUITMENT OF EZH2 AND H3K27ME3 ON THE PROMOTER OF TUMOR-SUPPRESSOR GENE PTEN IN CML CELLS WAS MEASURED BY CHROMATIN IMMUNOPRECIPITATION ASSAY.RESULTS: OUR RESULTS SHOWED THAT PHARMACOLOGIC INHIBITION OF EZH2 BY GSK126 NOT ONLY ELICITED APOPTOSIS AND RESTRICTED CELL GROWTH IN CML BULK LEUKEMIA CELLS, BUT ALSO DECREASED LSCS IN CML CD34(+) CELLS WHILE SPARING THOSE FROM NORMAL BONE MARROW CD34(+) CELLS. SUPPRESSION OF EZH2 BY GSK126 OR SPECIFIC SHRNA PROLONGED SURVIVAL OF CML MICE AND REDUCED THE NUMBER OF LSCS IN MICE. EZH2 KNOCKDOWN RESULTED IN ELEVATION OF PTEN AND LED TO IMPAIRED RECRUITMENT OF EZH2 AND H3K27ME3 ON THE PROMOTER OF PTEN GENE. THE EFFECT OF EZH2 KNOCKDOWN IN THE CML MICE WAS AT LEAST PARTIALLY REVERSED BY PTEN KNOCKDOWN.CONCLUSIONS: THESE FINDINGS IMPROVE THE UNDERSTANDING OF THE EPIGENETIC REGULATION OF STEMNESS IN CML LSCS AND WARRANT CLINICAL TRIAL OF GSK126 IN REFRACTORY PATIENTS WITH CML. CLIN CANCER RES; 24(1); 145-57. (C)2017 AACR. 2018 14 5902 32 T-HELPER 17 CELL POLARIZATION IN PULMONARY ARTERIAL HYPERTENSION. BACKGROUND: INFLAMMATION MAY CONTRIBUTE TO THE PATHOBIOLOGY OF PULMONARY ARTERIAL HYPERTENSION (PAH). DECIPHERING THE PAH FINGERPRINT ON THE INFLAMMATION ORCHESTRATED BY DENDRITIC CELLS (DCS) AND T CELLS, KEY DRIVER AND EFFECTOR CELLS, RESPECTIVELY, OF THE IMMUNE SYSTEM, MAY ALLOW THE IDENTIFICATION OF IMMUNOPATHOLOGIC APPROACHES TO PAH MANAGEMENT. METHODS: USING FLOW CYTOMETRY, WE PERFORMED IMMUNOPHENOTYPING OF MONOCYTE-DERIVED DCS (MODCS) AND CIRCULATING LYMPHOCYTES FROM PATIENTS WITH IDIOPATHIC PAH AND CONTROL SUBJECTS. WITH THE SAME TECHNIQUE, WE PERFORMED CYTOKINE PROFILING OF BOTH POPULATIONS FOLLOWING STIMULATION, COCULTURE, OR BOTH. WE TESTED THE IMMUNOMODULATORY EFFECTS OF A GLUCOCORTICOID (DEXAMETHASONE [DEX]) ON THIS IMMUNOPHENOTYPE AND CYTOKINE PROFILE. USING AN EPIGENETIC APPROACH, WE CONFIRMED THE IMMUNE POLARIZATION IN BLOOD DNA OF PATIENTS WITH PAH. RESULTS: THE PROFILE OF MEMBRANE COSTIMULATORY MOLECULES OF PAH MODCS WAS SIMILAR TO THAT OF CONTROL SUBJECTS. HOWEVER, PAH MODCS RETAINED HIGHER LEVELS OF THE T-CELL ACTIVATING MOLECULES CD86 AND CD40 AFTER DEX PRETREATMENT THAN DID CONTROL MODCS. THIS WAS ASSOCIATED WITH AN INCREASED EXPRESSION OF IL-12P40 AND A REDUCED MIGRATION TOWARD CHEMOKINE (C-C MOTIF) LIGAND 21. MOREOVER, BOTH WITH AND WITHOUT DEX, PAH MODCS INDUCED A HIGHER ACTIVATION AND PROLIFERATION OF CD4+ T CELLS, ASSOCIATED WITH A REDUCED EXPRESSION OF IL-4 (T HELPER 2 RESPONSE) AND A HIGHER EXPRESSION OF IL-17 (T HELPER 17 RESPONSE). PURIFIED PAH CD4+ T CELLS EXPRESSED A HIGHER LEVEL OF IL-17 AFTER ACTIVATION THAN DID THOSE OF CONTROL SUBJECTS. LASTLY, THERE WAS SIGNIFICANT HYPOMETHYLATION OF THE IL-17 PROMOTER IN THE PAH BLOOD DNA AS COMPARED WITH THE CONTROL BLOOD. CONCLUSIONS: WE HAVE HIGHLIGHTED T HELPER 17 CELL IMMUNE POLARIZATION IN PATIENTS WITH PAH, AS HAS BEEN PREVIOUSLY DEMONSTRATED IN OTHER CHRONIC INFLAMMATORY AND AUTOIMMUNE CONDITIONS. 2015 15 439 29 ANTILEUKEMIC ACTIVITY OF VALPROIC ACID IN CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS DEFINED BY MICROARRAY ANALYSIS. EPIGENETIC CODE MODIFICATIONS BY HISTONE DEACETYLASE INHIBITORS HAVE RECENTLY BEEN PROPOSED AS POTENTIAL NEW THERAPIES FOR HEMATOLOGICAL MALIGNANCIES. CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) REMAINS INCURABLE DESPITE THE INTRODUCTION OF NEW TREATMENTS. CLL B CELLS ARE CHARACTERIZED BY AN APOPTOSIS DEFECT RATHER THAN EXCESSIVE PROLIFERATION, BUT PROLIFERATION CENTERS HAVE BEEN FOUND IN ORGANS SUCH AS THE BONE MARROW AND LYMPH NODES. IN THIS STUDY, WE ANALYZED GENE EXPRESSION MODIFICATIONS IN CLL B CELLS AFTER TREATMENT WITH VALPROIC ACID (VPA), A WELL-TOLERATED ANTI-EPILEPTIC DRUG WITH HDAC INHIBITORY ACTIVITY. CLL B CELLS OBTAINED FROM 14 PATIENTS WERE TREATED IN VITRO WITH A CONCENTRATION OF 1 MM VPA FOR 4 H. VPA EFFECTS ON GENE EXPRESSION WERE THEREAFTER STUDIED USING AFFYMETRIX TECHNOLOGY, AND SOME IDENTIFIED GENES WERE VALIDATED BY REAL-TIME PCR AND WESTERN BLOT. WE OBSERVED THAT VPA INDUCED APOPTOSIS BY DOWNREGULATING SEVERAL ANTI-APOPTOTIC GENES AND BY UPREGULATING PRO-APOPTOTIC GENES. FURTHERMORE, VPA SIGNIFICANTLY INCREASED CHEMOSENSITIVITY TO FLUDARABINE, FLAVOPIRIDOL, BORTEZOMIB, THALIDOMIDE AND LENALIDOMIDE. VPA INHIBITED THE PROLIFERATION OF CPG/IL2-STIMULATED CLL B CELLS AND MODULATED MANY CELL CYCLE MESSENGER RNAS. IN CONCLUSION, EXPOSURE OF CLL B CELLS TO VPA INDUCED APOPTOSIS, POTENTIATED CHEMOTHERAPEUTIC AGENT EFFECTS AND INHIBITED PROLIFERATION. THESE DATA STRONGLY SUGGEST THE USE OF VPA IN CLL TREATMENT, PARTICULARLY IN COMBINATION WITH ANTILEUKEMIA AGENTS. 2009 16 66 27 A KEY ROLE FOR EZH2 IN EPIGENETIC SILENCING OF HOX GENES IN MANTLE CELL LYMPHOMA. THE CHROMATIN MODIFIER EZH2 IS OVEREXPRESSED AND ASSOCIATED WITH INFERIOR OUTCOME IN MANTLE CELL LYMPHOMA (MCL). RECENTLY, WE DEMONSTRATED PREFERENTIAL DNA METHYLATION OF HOX GENES IN MCL COMPARED WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), DESPITE THESE GENES NOT BEING EXPRESSED IN EITHER ENTITY. SINCE EZH2 HAS BEEN SHOWN TO REGULATE HOX GENE EXPRESSION, TO GAIN FURTHER INSIGHT INTO ITS POSSIBLE ROLE IN DIFFERENTIAL SILENCING OF HOX GENES IN MCL VS. CLL, WE PERFORMED DETAILED EPIGENETIC CHARACTERIZATION USING REPRESENTATIVE CELL LINES AND PRIMARY SAMPLES. WE OBSERVED SIGNIFICANT OVEREXPRESSION OF EZH2 IN MCL VS. CLL. CHROMATIN IMMUNE PRECIPITATION (CHIP) ASSAYS REVEALED THAT EZH2 CATALYZED REPRESSIVE H3 LYSINE 27 TRIMETHYLATION (H3K27ME3), WHICH WAS SUFFICIENT TO SILENCE HOX GENES IN CLL, WHEREAS IN MCL H3K27ME3 IS ACCOMPANIED BY DNA METHYLATION FOR A MORE STABLE REPRESSION. MORE IMPORTANTLY, HYPERMETHYLATION OF THE HOX GENES IN MCL RESULTED FROM EZH2 OVEREXPRESSION AND SUBSEQUENT RECRUITMENT OF THE DNA METHYLATION MACHINERY ONTO HOX GENE PROMOTERS. THE IMPORTANCE OF EZH2 UPREGULATION IN THIS PROCESS WAS FURTHER UNDERSCORED BY SIRNA TRANSFECTION AND EZH2 INHIBITOR EXPERIMENTS. ALTOGETHER, THESE OBSERVATIONS IMPLICATE EZH2 IN THE LONG-TERM SILENCING OF HOX GENES IN MCL, AND ALLUDE TO ITS POTENTIAL AS A THERAPEUTIC TARGET WITH CLINICAL IMPACT. 2013 17 3175 33 H2AX PHOSPHORYLATION REGULATED BY P38 IS INVOLVED IN BIM EXPRESSION AND APOPTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA CELLS INDUCED BY IMATINIB. INCREASING EVIDENCE SUGGESTS THAT HISTONE H2AX PLAYS A CRITICAL ROLE IN REGULATION OF TUMOR CELL APOPTOSIS AND ACTS AS A NOVEL HUMAN TUMOR SUPPRESSOR PROTEIN. HOWEVER, THE ACTION OF H2AX IN CHRONIC MYELOGENOUS LEUKEMIA (CML) CELLS IS UNKNOWN. THE DETAILED MECHANISM AND EPIGENETIC REGULATION BY H2AX REMAIN ELUSIVE IN CANCER CELLS. HERE, WE REPORT THAT H2AX WAS INVOLVED IN APOPTOSIS OF CML CELLS. OVEREXPRESSION OF H2AX INCREASED APOPTOTIC SENSITIVITY OF CML CELLS (K562) INDUCED BY IMATINIB. HOWEVER, OVEREXPRESSION OF SER139-MUTATED H2AX (BLOCKING PHOSPHORYLATION) DECREASED SENSITIVITY OF K562 CELLS TO APOPTOSIS. SIMILARLY, KNOCKDOWN OF H2AX MADE K562 CELLS RESISTANT TO APOPTOTIC INDUCTION. THESE RESULTS REVEALED THAT THE FUNCTION OF H2AX INVOLVED IN APOPTOSIS IS STRICTLY RELATED TO ITS PHOSPHORYLATION (SER139). OUR DATA FURTHER INDICATED THAT IMATINIB MAY STIMULATE MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) FAMILY MEMBER P38, AND H2AX PHOSPHORYLATION FOLLOWED A SIMILAR TIME COURSE, SUGGESTING A PARALLEL RESPONSE. H2AX PHOSPHORYLATION CAN BE BLOCKED BY P38 SIRNA OR ITS INHIBITOR. THESE DATA DEMONSTRATED THAT H2AX PHOSPHORYLATION WAS REGULATED BY P38 MAPK PATHWAY IN K562 CELLS. HOWEVER, THE P38 MAPK DOWNSTREAM, MITOGEN- AND STRESS-ACTIVATED PROTEIN KINASE-1 AND -2, WHICH PHOSPHORYLATED HISTONE H3, WERE NOT REQUIRED FOR H2AX PHOSPHORYLATION DURING APOPTOSIS. FINALLY, WE PROVIDED EPIGENETIC EVIDENCE THAT H2AX PHOSPHORYLATION REGULATED APOPTOSIS-RELATED GENE BIM EXPRESSION. BLOCKING OF H2AX PHOSPHORYLATION INHIBITED BIM GENE EXPRESSION. TAKEN TOGETHER, THESE DATA DEMONSTRATED THAT H2AX PHOSPHORYLATION REGULATED BY P38 IS INVOLVED IN BIM EXPRESSION AND APOPTOSIS IN CML CELLS INDUCED BY IMATINIB. 2014 18 3894 28 LAMIN B1 REGULATES SOMATIC MUTATIONS AND PROGRESSION OF B-CELL MALIGNANCIES. SOMATIC HYPERMUTATION (SHM) IS A PIVOTAL PROCESS IN ADAPTIVE IMMUNITY THAT OCCURS IN THE GERMINAL CENTRE AND ALLOWS B CELLS TO CHANGE THEIR PRIMARY DNA SEQUENCE AND DIVERSIFY THEIR ANTIGEN RECEPTORS. HERE, WE REPORT THAT GENOME BINDING OF LAMIN B1, A COMPONENT OF THE NUCLEAR ENVELOPE INVOLVED IN EPIGENETIC CHROMATIN REGULATION, IS REDUCED DURING B-CELL ACTIVATION AND FORMATION OF LYMPHOID GERMINAL CENTRES. CHROMATIN IMMUNOPRECIPITATION-SEQ ANALYSIS SHOWED THAT KAPPA AND HEAVY VARIABLE IMMUNOGLOBULIN DOMAINS WERE RELEASED FROM THE LAMIN B1 SUPPRESSIVE ENVIRONMENT WHEN SHM WAS INDUCED IN B CELLS. RNA INTERFERENCE-MEDIATED REDUCTION OF LAMIN B1 RESULTED IN SPONTANEOUS SHM AS WELL AS KAPPA-LIGHT CHAIN ABERRANT SURFACE EXPRESSION. FINALLY, LAMIN B1 EXPRESSION LEVEL CORRELATED WITH PROGRESSION-FREE AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKAEMIA, AND WAS STRONGLY INVOLVED IN THE TRANSFORMATION OF FOLLICULAR LYMPHOMA. IN SUMMARY, HERE WE REPORT THAT LAMIN B1 IS A NEGATIVE EPIGENETIC REGULATOR OF SHM IN NORMAL B-CELLS AND A 'MUTATIONAL GATEKEEPER', SUPPRESSING THE ABERRANT MUTATIONS THAT DRIVE LYMPHOID MALIGNANCY. 2018 19 3373 34 HISTONE MODULATION BLOCKS TREG-INDUCED FOXP3 BINDING TO THE IL-2 PROMOTER OF VIRUS-SPECIFIC CD8(+) T CELLS FROM FELINE IMMUNODEFICIENCY VIRUS-INFECTED CATS. CD8(+) T CELLS ARE CRITICAL FOR CONTROLLING HIV INFECTION. DURING THE CHRONIC PHASE OF LENTIVIRAL INFECTION, CD8(+) T CELLS LOSE THEIR PROLIFERATIVE CAPACITY AND EXHIBIT IMPAIRED ANTIVIRAL FUNCTION. THIS LOSS OF CD8(+) T CELL FUNCTION IS DUE, IN PART, TO CD4(+)CD25(+) T REGULATORY (TREG) CELL-MEDIATED SUPPRESSION. OUR RESEARCH GROUP HAS DEMONSTRATED THAT LENTIVIRUS-ACTIVATED CD4(+)CD25(+) TREG CELLS INDUCE THE REPRESSIVE TRANSCRIPTION FACTOR FORKHEAD BOX P3 (FOXP3) IN AUTOLOGOUS CD8(+) T CELLS FOLLOWING CO-CULTURE. WE HAVE RECENTLY REPORTED THAT TREG-INDUCED FOXP3 BINDS THE INTERLEUKIN-2 (IL-2), INTERFERON-GAMMA (IFN- GAMMA), AND TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) PROMOTERS IN VIRUS-SPECIFIC CD8(+) T CELLS. THESE DATA SUGGEST AN IMPORTANT ROLE OF FOXP3-MEDIATED CD8(+) T CELL DYSFUNCTION IN LENTIVIRAL INFECTION. TO ELUCIDATE THE MECHANISM OF THIS SUPPRESSION, WE PREVIOUSLY REPORTED THAT DECREASED METHYLATION FACILITATES FOXP3 BINDING IN MITOGEN-ACTIVATED CD8(+) T CELLS FROM FELINE IMMUNODEFICIENCY VIRUS (FIV)-INFECTED CATS. WE DEMONSTRATED THE REDUCED BINDING OF FOXP3 TO THE IL-2 PROMOTER BY INCREASING METHYLATION OF CD8(+) T CELLS. IN THE STUDIES PRESENTED HERE, WE ASK IF ANOTHER FORM OF EPIGENETIC MODULATION MIGHT ALLEVIATE FOXP3-MEDIATED SUPPRESSION IN CD8(+) T CELLS. WE HYPOTHESIZED THAT DECREASING HISTONE ACETYLATION IN VIRUS-SPECIFIC CD8(+) T CELLS WOULD DECREASE TREG-INDUCED FOXP3 BINDING TO THE IL-2 PROMOTER. INDEED, USING ANACARDIC ACID (AA), A KNOWN HISTONE ACETYL TRANSFERASE (HAT) INHIBITOR, WE DEMONSTRATE A REDUCTION IN FOXP3 BINDING TO THE IL-2 PROMOTER IN VIRUS-SPECIFIC CD8(+) T CELLS CO-CULTURED WITH AUTOLOGOUS TREG CELLS. THESE DATA IDENTIFY A NOVEL MECHANISM OF FOXP3-MEDIATED CD8(+) T CELL DYSFUNCTION DURING LENTIVIRAL INFECTION. 2018 20 2392 24 EPIGENETIC REPRESSION OF INTERLEUKIN 2 EXPRESSION IN SENESCENT CD4+ T CELLS DURING CHRONIC HIV TYPE 1 INFECTION. THE MOLECULAR MECHANISMS FOR IL2 GENE-SPECIFIC DYSREGULATION DURING CHRONIC HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION ARE UNKNOWN. HERE, WE INVESTIGATED THE ROLE OF DNA METHYLATION IN SUPPRESSING INTERLEUKIN 2 (IL-2) EXPRESSION IN MEMORY CD4(+) T CELLS DURING CHRONIC HIV-1 INFECTION. WE OBSERVED THAT CPG SITES IN THE IL2 PROMOTER OF CD4(+) T CELLS WERE FULLY METHYLATED IN NAIVE CD4(+) T CELLS AND SIGNIFICANTLY DEMETHYLATED IN THE MEMORY POPULATIONS. INTERESTINGLY, WE FOUND THAT THE MEMORY CELLS THAT HAD A TERMINALLY DIFFERENTIATED PHENOTYPE AND EXPRESSED CD57 HAD INCREASED IL2 PROMOTER METHYLATION RELATIVE TO LESS DIFFERENTIATED MEMORY CELLS IN HEALTHY INDIVIDUALS. IMPORTANTLY, EARLY EFFECTOR MEMORY SUBSETS FROM HIV-1-INFECTED SUBJECTS EXPRESSED HIGH LEVELS OF CD57 AND WERE HIGHLY METHYLATED AT THE IL2 LOCUS. FURTHERMORE, THE INCREASED CD57 EXPRESSION ON MEMORY CD4(+) T CELLS WAS INVERSELY CORRELATED WITH IL-2 PRODUCTION. THESE DATA SUGGEST THAT DNA METHYLATION AT THE IL2 LOCUS IN CD4(+) T CELLS IS COUPLED TO IMMUNOSENESCENCE AND PLAYS A CRITICAL ROLE IN THE BROAD DYSFUNCTION THAT OCCURS IN POLYCLONAL T CELLS DURING HIV-1 INFECTION. 2015